Abstract:ABSTRACT Rotavirus causes severe diarrhea in infants. Although live attenuated rotavirus vaccines are available, vaccine-derived infections have been reported, which warrants development of next-generation rotavirus vaccines. A single-round infectious virus is a promising vaccine platform; however, this platform has not been studied extensively in the context of rotavirus. Here, we aimed to develop a single-round infectious rotavirus by impairing the function of the viral intermediate capsid protein VP6. Recombinant rotaviruses harboring mutations in VP6 were rescued using a reverse genetics system. Mutations were targeted at VP6 residues involved in virion assembly. Although the VP6-mutated rotavirus expressed viral proteins, it did not produce progeny virions in wild-type cells; however, the virus did produce progeny virions in VP6-expressing cells. This indicates that the VP6-mutated rotavirus is a single-round infectious rotavirus. Insertion of a foreign gene, and replacement of the VP7 gene segment with that of human rotavirus clinical isolates, was successful. No infectious virions were detected in mice infected with the single-round infectious rotavirus. Immunizing mice with the single-round infectious rotavirus induced neutralizing antibody titers as high as those induced by wild-type rotavirus. Taken together, the data suggest that this single-round infectious rotavirus has potential as a safe and effective rotavirus vaccine. This system is also applicable for generation of safe and orally administrable viral vectors. IMPORTANCE Rotavirus, a leading cause of acute gastroenteritis in infants, causes an annual estimated 128,500 infant deaths worldwide. Although live attenuated rotavirus vaccines are available, they are replicable and may cause vaccine-derived infections. Thus, development of safe and effective rotavirus vaccine is important. In this study, we report the development of a single-round infectious rotavirus that can replicate only in cells expressing viral VP6 protein. We demonstrated that (1) the single-round infectious rotavirus did not replicate in wild-type cells or in mice; (2) insertion of foreign genes and replacement of the outer capsid gene were possible; and (3) it was as immunogenic as the wild-type virus. Thus, the mutated virus shows promise as a next-generation rotavirus vaccine. The system is also applicable to orally administrable viral vectors, facilitating development of vaccines against other enteric pathogens.

A Milk-Based Self-Assemble Rotavirus VP6–ferritin Nanoparticle Vaccine Elicited Protection Against the Viral Infection

Self-assembling Rotavirus VP6 Nanoparticle Vaccines Expressed in Escherichia Coli Elicit Systemic and Mucosal Responses in Mice.

Establishment of a Soluble Expression and Rapid Purification System for Self-Assembling Protein Nanoparticle and Characterization of Its Physiochemical Properties

Improved Characteristics and Protective Efficacy in an Animal Model of E. Coli-Derived Recombinant Double-Layered Rotavirus Virus-Like Particles

Rotavirus VP6 protein mucosally delivered by cell wall-derived particles from Lactococcus lactis induces protection against infection in a murine model

Safety, Immunogenicity, and Mechanism of a Rotavirus mRNA-LNP Vaccine in Mice

Lactobacillus acidophilus Expressing Murine Rotavirus VP8 and Mucosal Adjuvants Induce Virus-Specific Immune Responses

Characterization and Protective Efficacy in an Animal Model of a Novel Truncated Rotavirus VP8 Subunit Parenteral Vaccine Candidate.

Molecular Design of Encapsulin Protein Nanoparticles to Display Rotavirus Antigens for Enhancing Immunogenicity

Immunogenicity and protective efficacy of rotavirus VP8* fused to cholera toxin B subunit in a mouse model

VP8 Mosaic Nanoparticles Elicit Cross-Neutralizing Immune Responses and Provide Protection Against Heterotypic Rotavirus Challenge in Mice

Generation of single-round infectious rotavirus with a mutation in the intermediate capsid protein VP6

Parenterally Administered P24-VP8* Nanoparticle Vaccine Conferred Strong Protection against Rotavirus Diarrhea and Virus Shedding in Gnotobiotic Pigs

A Self-Assembling Nanoparticle: Implications for the Development of Thermostable Vaccine Candidates.

Immunogenicity of a Rotavirus VP8* Multivalent Subunit Vaccine in Mice

Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates.

A ferritin nanoparticle vaccine for foot-and-mouth disease virus elicited partial protection in mice

Virus-like Particles vaccine based on co-expression of G5 Porcine rotavirus VP2-VP6-VP7 induces a powerful immune protective response in mice

Effects of Rotavirus NSP4 on the Immune Response and Protection of Rotavirus-Norovirus Recombinant Subunit Vaccines in Different Immune Pathways

Inclusion of a Universal Tetanus Toxoid CD4+ T Cell Epitope P2 Significantly Enhanced the Immunogenicity of Recombinant Rotavirus ΔVP8* Subunit Parenteral Vaccines

Tandem Truncated Rotavirus VP8* Subunit Protein with T Cell Epitope As Non-Replicating Parenteral Vaccine is Highly Immunogenic